ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0322

Enhanced Detection of Myocarditis in Idiopathic Inflammatory Myopathies Utilizing Multiparametric Cardiac Magnetic Resonance Imaging

Julie Paik1, Shadi Ayoumi2, Ghazal Zandieh2, Cody Calhoun2, Caoilfhionn Connolly2, Lisa Christopher-Stine1, Christopher Mecoli1, Myma Albayda2, Eleni Tiniakou3, Nisha Gilotra2, Stefan Zimmerman2 and Bharath Venkatesh2, 1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Johns Hopkins University, Lutherville Timonium, MD

Meeting: ACR Convergence 2024

Keywords: Myocarditis, Myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Myocarditis in idiopathic inflammatory myopathies (IIM) is poorly understood despite its association with poor outcomes such as heart failure and sudden cardiac death. It is important to detect myocarditis early to potentially escalate immunosuppressive treatment. The purpose of this study was to determine whether multiparametric cardiac MRI can better quantify and detect myocarditis including subclinical disease in IIM.

Methods: We performed a prospective pilot study of patients with IIM (excluding inclusion body myositis)  within first year of disease onset to rigorously screen for myocarditis with cardiac biomarkers including high-sensitivity troponin-I and pro-BNP, EKG, echocardiogram, and multiparametric cardiac MRI. Clinically suspected myocarditis was defined by the 2013 European Society of Cardiology (ESC) for clinically suspected myocarditis and confirmed by the 2018 Lake Louise Criteria for myocarditis on cardiac MRI. Advanced multiparametric parameters on cardiac MRI such as T1 and T2 maps, and extracellular volume fraction (ECV) and quantification of late gadolinium enhancement were obtained.  Differences in clinical characteristics and multiparametric values were compared between patients with and without a myocarditis using student’s t-tests and Fischer’s exact test as appropriate

Results: 26 patients with myositis were screened for myocarditis and 7 of 26 (26%) met the ESC criteria for clinically suspected myocarditis and the 2018 Lake Louise Criteria for myocarditis on cardiac MRI. The most common IIM subgroup that that had myocarditis was the overlap IIM with scleroderma (5 of 7, 71%) and anti-synthetase syndrome (ASyS) (2 of 7, 29%). When compared to those without myocarditis, anti-Ku was more prevalent in those with myocarditis (p=0.003), while cardiac events such as heart failure (EF< 50%) or arrhythmia were more prevalent in those with myocarditis (42.8% vs. 6.2%, p=0.02). Multiparametric cardiac MRI demonstrated that IIM patients with myocarditis had elevated T1, T2, and ECV maps when compared to those without myocarditis, and late gadolinium enhancement (LGE) was higher in those with myocarditis compared to those without myocarditis (6.16 + 5.52 % vs. 0.22 + 0.37%, p=0.0006) (Table 1). Interestingly, the greatest degree of LGE ( >5%) was found in those who were anti-Ku positive.  Among IIM patients without myocarditis,  T1 and T2 map values were elevated compared to historical healthy controls indicating subclinical myocardial edema(T1map values: 1040 + 68.3 vs 963.9 + 32.5 ,p=0.0012 and T2 map values: 57.3 + 1.73 vs 52.8 + 4.4, p=0.0004).

Conclusion: In this preliminary study of myocarditis in IIM with disease onset within 1 year, myocarditis was associated with a higher frequency of poor outcomes. Advanced multiparametric CMR quantified the extent and burden of myocarditis by assessing myocardial edema and fibrosis using T1 and T2 maps, ECV, and quantification of LGE. Overall, T1 and T2 maps were higher even in those without myocarditis highlighting that low grade myocardial edema may be present even in those without symptoms or elevated cardiac biomarkers

Supporting image 1

Table 1. Multiparametric CMR parameters in those with and without myocarditis. Patients with myocarditis had elevated ECV, depressed LVEF, increased late gadolinium enhancement when compared to those without myocarditis that was statistically significant. There was also a trend for higher T2 and T1 maps in those with myocarditis when compared to those without myocarditis


Disclosures: J. Paik: ArgenX, 2, 5, AstraZeneca, 5, Guidepoint Consulting, 2, Pfizer, 2, Priovant, 5; S. Ayoumi: None; G. Zandieh: None; C. Calhoun: None; C. Connolly: None; L. Christopher-Stine: Allogene, 2, ArgenX, 2, Boehringer-Ingelheim, 2, Corbus Pharmaceuticals, 5, Dysimmune Disease Foundation, 2, EMD Serono, 2, Horizon, 5, Janssen, 5, Kezar Life Sciences, 5, Mallinckrodt, 2, Octapharma, 2, Pfizer Inc, 5, Priovant Therapeutics, 2, Roivant Sciences, 2; C. Mecoli: Argenx, 1, Department of Justice, 2; M. Albayda: None; E. Tiniakou: None; N. Gilotra: Kiniksa Pharmaceuticals, 2; S. Zimmerman: None; B. Venkatesh: None.

To cite this abstract in AMA style:

Paik J, Ayoumi S, Zandieh G, Calhoun C, Connolly C, Christopher-Stine L, Mecoli C, Albayda M, Tiniakou E, Gilotra N, Zimmerman S, Venkatesh B. Enhanced Detection of Myocarditis in Idiopathic Inflammatory Myopathies Utilizing Multiparametric Cardiac Magnetic Resonance Imaging [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/enhanced-detection-of-myocarditis-in-idiopathic-inflammatory-myopathies-utilizing-multiparametric-cardiac-magnetic-resonance-imaging/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/enhanced-detection-of-myocarditis-in-idiopathic-inflammatory-myopathies-utilizing-multiparametric-cardiac-magnetic-resonance-imaging/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology